Yara Kadria-Vili

Dr. Yara Kadria-Vili

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 July 2024 in Nanomaterials
Verified
Journal Article
Open access
PDF file
YKYara Kadria-Vili
Yara Kadria-Vili
JSJon A. Schwartz
Jon A. Schwartz
TPThomas J. Polascik
Thomas J. Polascik
GGGlenn P. Goodrich
Glenn P. Goodrich
DJDavid Jorden
David Jorden
ARArdeshir R Rastinehad
Ardeshir R Rastinehad
AuroLase® Therapy—a nanoparticle-enabled focal therapy—has the potential to safely and effectively treat localized prostate cancer (PCa), preserving baseline functionality. This article presents a detailed case of localized PCa treated with AuroLase, providing insight on expectations from the diagnosis of PCa to one year post-treatment. AuroLase Therapy is a two-day treatment consisting of a systemic infusion of gold nanoshells (~150-nm hydrodynamic diameter) on Day 1, and sub-ablative laser treatment on Day 2. Multiparametric MRI (mpMRI) was used for tumor visualization, treatment planning, and therapy response assessment. The PCa was targeted with a MR/Ultrasound-fusion (MR/US) transperineal approach. Successful treatment was confirmed at 6 and 12 months post-treatment by the absence of disease in MR/US targeted biopsies. On the mpMRI, confined void space was evident, an indication of necrotic tissues encompassing the treated lesion, which was completely resolved at 12 months, forming a band-like scar with no evidence of recurrent tumor. The patient’s urinary and sexual functions were unchanged. During the one-year follow-up, changes on the DCE sequence and in the Ktrans and ADC values assist in qualitatively and quantitatively evaluating tissue changes. The results highlight the potential of gold-nanoparticle-enabled sub-ablative laser treatment to target and control localized PCa, maintain quality of life, and preserve baseline functionality.

1 December 2024 in Journal of Urology
Verified
Journal Article
Open access
SCSteven E. Canfield
Steven E. Canfield
AGArvin K. George
Arvin K. George
JJJoshua Jue
Joshua Jue
SLSara Lewis
Sara Lewis
MDMatthew S. Davenport
Matthew S. Davenport
ARArdeshir R Rastinehad
Ardeshir R Rastinehad
Focal therapy aims to provide a durable oncological treatment option for men with prostate cancer (PCa), while preserving their quality of life. Most focal therapy modalities rely on the direct tissue effect, resulting in a possible nontargeted approach to ablation. Here, we report the results of the first human feasibility trial utilizing nanoparticle-directed focal photothermal ablation for PCa. A prospective open-label, single-arm multicenter study of men with localized PCa in the Gleason Grade Group (GGG) 1 to 3 was conducted. Men received a single infusion of gold nanoparticles (AuroShells), followed by MR/US fusion-guided laser excitation of the target tissue to induce photothermal ablation. MRI was used to assess the effectiveness of prostate tissue ablation at 48 to 96 hours, 3-months, and 12-months post-treatment. At 3 months, a targeted fusion biopsy of the lesion(s) was conducted. At 12 months a targeted fusion biopsy and standard templated biopsy were performed. Treatment success was determined based on a negative MR/US fusion biopsy outcome within the treated area. Forty-six men were enrolled in the study, and 44 men with 45 lesions completed nanoparticles infusion and laser treatment. The mean PSA level at baseline was 9.5 ng/mL, which decreased 5.9 ng/mL at 3-months and 4.7 ng/mL at 12-months (P < .0001). The oncologic success rates at 3- and 12-months resulted in 29 (66%) and 32 (73%) of 44 patients, respectively, being successfully treated confirmed with negative MR/US fusion biopsies within the ablation zone. Among GGG, maximum-lesion-diameter (MLD) on MRI, prostate volume, and PI-RADS scoring, the MLD was significantly associated with the odds of treatment failure at 12-months (P = .046). Nanoparticle-directed focal laser ablation of neoplastic prostate tissue resulted in 73% patients with successful treatment at 12-months post-treatment, confirmed by negative MR/US fusion biopsy of the treated lesion and a systematic biopsy.